The clinical performance is complex and often involves multi-systematic stress. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to closely monitor efficacy and adverse reactions, adapting timely to changes in the course of the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of the socio-economic context of HL. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, who provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.